Carmustine: profile and news

MGI PHARMA To Present at the Lehman Brothers 9th Annual Global ...  Mar 3, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - Genetic Engineering News,

CANCER WONDER DRUGS BLOCKED  Feb 25, 2006
Yesterday, Mrs Mitchell accused the NHS of ignoring evidence showing that temozolomide and carmustine were effective and good value for money. ... - Bristol Evening Post,

Doctors demand brain tumour drugs  Feb 22, 2006
...patients' needs. They say the treatments, temozolomide and carmustine implants, are a major advance, and value for money. NICE initially ... - BBC News,

NHS watchdog 'ignoring cancer patients' needs'  Feb 23, 2006
A preliminary decision by the National Institute for Clinical Excellence (NICE) did not recommend the treatments - temozolomide and carmustine implants - on ... - Daily Mail - UK,

Cancer specialists hail "big breakthroughs" in brain tumour ...  Feb 23, 2006
..."Nice has yet to produce guidance to the NHS on the use of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (brain ... - 24dash.com,

Docs lobby minister over cancer drug  Feb 23, 2006
A Department of Health spokeswoman said: "Nice has yet to produce guidance to the NHS on the use of carmustine implants and temozolomide for the treatment of ... - Glasgow Evening Times,

CORRECTING and REPLACING MGI PHARMA Reports Fourth Quarter and ...  Feb 9, 2006
2004. Sales of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) were $8.5 million for the fourth quarter of 2005. Total ... - Genetic Engineering News,

CORRECTING and REPLACING MGI PHARMA Reports Fourth Quarter and ...  09 Feb 2006
2004. Sales of Gliadel(R) Wafer(polifeprosan 20 with carmustine implant) were $8.5 million for thefourth quarter of 2005. Total ... - Finanzen.net,

MGI PHARMA to Present at the BIO CEO and Investor Conference  Feb 7, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - Genetic Engineering News,

NeoPharm Announces Completion of PRECISE Trial Enrollment as Per ...  Dec 9, 2005
A GLIADEL(R) Wafer delivers BCNU (or carmustine), a commonly used chemotherapeutic anti-tumor agent for GBM, directly to the brain tumor resection cavity. ... - Genetic Engineering News,

MGI PHARMA Announces Expiration of Tender Offer for Guilford ...  Nov 29, 2005
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - Business Wire (press release),

GSW Worldwide to Lead SaforisTM Launch Campaign for MGI PHARMA ...  Nov 14, 2005
MGI PHARMA markets Aloxi ® (palonosetron hydrochloride) injection and Gliadel ® Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - PharmaLive.com (press release),

MGI PHARMA Completes Acquisition of Guilford Pharmaceuticals  Oct 3, 2005
Gliadel (polifeprosan 20 with carmustine implant) Wafer is a biodegradable wafer containing the chemotherapy agent carmustine, or BCNU, approved for the ... - Genetic Engineering News,

MGI PHARMA Reports Third Quarter Financial Results  Oct 19, 2005
...of marketed oncology products with the addition of Aquavan(R) (fospropofol disodium) injection and Gliadel(R) wafer (polifeprosan 20 with carmustine implant). ... - Business Wire (press release),

Guilford Pharmaceuticals Stockholders Vote to Approve MGI PHARMA ...  Sep 30, 2005
Presently, Guilford markets two commercial products, Gliadel(R) wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, and ... - PharmaLive.com (press release),

Zevalin® May Substitute for Total Body Irradiation When Combined ...  Oct 6, 2005
...have suggested that higher doses of Zevalin can be administered in combination with the common transplant regimen of BEAM (carmustine, etoposide, cytarabine ... - Cancer Consultants (press release),

Guilford Pharmaceuticals Stockholders Vote to Approve MGI PHARMA ...  Sep 29, 2005
Presently, Guilford markets two commercial products, Gliadel(R) wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, and ... - PR Newswire (press release),

MGI PHARMA Completes Acquisition of Guilford Pharmaceuticals  Oct 3, 2005
Gliadel (polifeprosan 20 with carmustine implant) Wafer is a biodegradable wafer containing the chemotherapy agent carmustine, or BCNU, approved for the ... - Genetic Engineering News,

Zevalin® May Substitute for Total Body Irradiation When Combined ...  Oct 6, 2005
...have suggested that higher doses of Zevalin can be administered in combination with the common transplant regimen of BEAM (carmustine, etoposide, cytarabine ... - Cancer Consultants (press release),

Mixed Outcomes for Radiosurgery in Brain Tumors  Sep 16, 2005
Adding radiosurgery to treatment with external beam radiation and the chemotherapy drug carmustine does not appear to improve survival compared to treatment ... - Cancer Consultants (press release),

Radiation Dose Escalation as Treatment for Clinically Localized ...  Sep 13, 2005
Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for ... - Journal of American Medical Association (subscription),

High-Dose Sequential Chemotherapy and Autologous Stem Cell ...  Sep 13, 2005
The transplant regimen was BEAM (cytarabine, etoposide, melphalan and carmustine). At the end of this therapy the complete response rate was 43%. ... - Cancer Consultants (press release),

High-Dose Sequential Chemotherapy and Autologous Stem Cell ...  08 Sep 2005
The transplant regimen was BEAM (cytarabine, etoposide, melphalan and carmustine). At the end of this therapy the complete response rate was 43%. ... - Cancer Consultants (press release),

MGI PHARMA and Guilford Pharmaceuticals Announce Expiration of the ...  Sep 1, 2005
Presently, Guilford markets two commercial products, Gliadel(R) wafer (polifeprosan 20 with carmustine implant), for the treatment of high grade malignant ... - Genetic Engineering News,

FDA Sends SuperGen Warning Letter Over Nipent Handout  Aug 22, 2005
...and hypotension, leading to death, have been reported in the literature in patients treated with pentostatin in combination with carmustine, etoposide and high ... - PharmaLive.com (press release),

New Microfluidics Device Can Deliver Targeted Anti-Cancer Drugs to ...  Aug 30, 2005
Institute of Technology has created a microfluidics device to provide sustained, local release of the potent anticancer drug carmustine, also known as BCNU. ... - AZoNano.com,

Zanosar® Superior to Doxorubicin for Advanced Carcinoid Tumors  Aug 2, 2005
Chemotherapy response rates are low and some of the agents studied include 5-fluorouracil, BiCNU® (carmustine), CeeNU® (lomustine), doxorubicin, dacarbazine ... - Cancer Consultants (press release)

MGI PHARMA to Acquire Guilford Pharmaceuticals  Jul 21, 2005
Gliadel wafer is a biodegradable wafer containing the chemotherapy agent carmustine, or BCNU, approved for the treatment of high grade malignant gliomas as an ... - Business Wire (press release)

MGI Pharma to acquire Guilford  Jul 21, 2005
...its own Aloxi product. Guilford also has developed a biodegradable wafer for the delivery of the chemotherapy agent carmustine. - MarketWatch

Temodar®/BiCNU® Prior to and Following Radiation Therapy in ...  Jul 20, 2005
French researchers have reported that Temodar (temozolomide) and BiCNU (carmustine) used prior to and following radiation therapy is a promising regimen in ... - Cancer Consultants (press release) <**results**>

Two Studies Show Zevalin® Effective in Elderly Patients with ...  Jun 30, 2005
Europe and the United States have reported that Zevalin (Yttrium 90 ibritumomab tiuxetan) alone or combined with high-dose carmustine, etoposide, cytarabine ... - Cancer Consultants (press release),

No information provided.